The second-edition “2023 US and Western Europe Cataract Pharmaceuticals Market Report” features new survey data and forecasts for the United States and Western European markets for cataract pharmaceuticals. The new data explore surgeon preferences for preventing infection, dilation, and managing inflammation and pain. The report now provides the market shares of leading competitors, analyzes pharmaceutical use in the United States by providers’ surgical volume, and studies the developmental pipeline for drugs and drug delivery.
The “2023 US and Western Europe Cataract Pharmaceuticals Market Report” offers an in-depth examination of the current cataract pharmaceuticals market in the United States and Western Europe and forecasts market performance over the next five years. The report analyzes the current market and forecasts units, average sales price, and revenue through 2028 by product category. It analyzes products currently on the market and examines the development pipeline, discusses the popularity of intracameral injections and fixed combination eye drops, and analyzes the roles of brand name medications, generics, and compounded formulations.
This comprehensive report covers the United States and Western European markets and provides:
2 licensing types are available for this report:
Both licenses include an electronic PDF. Printed copies may be purchased for an additional $250.
SINGLE USER LICENSE
ENTERPRISE LICENSE
Pay by credit card or by invoice.
A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.